Skip to main content

Table 2 Biochemical data before and after ezetimibe treatment

From: Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency

 

Patient 1

Patient 2

Patient 3

 

Baseline

E10

E10 + A10

Baseline

E10

E10 + A10

Baseline

E10

ALT (IU/L)

137.2 ± 37.1

79.1 ± 12.8**

88.5 ± 28.5**

186.7 ± 41.8

88.2 ± 26.5**

84.9 ± 21.1**

115.0

76.3 ± 7.2

TC (mmol/L)

7.36 ± 0.75

5.54 ± 0.50**

4.40 ± 0.82**†

7.98 ± 0.84

6.59 ± 1.22**

4.37 ± 0.42**†

7.70

5.92 ± 0.44

HDL-C (mmol/L)

0.96 ± 0.07

1.01 ± 0.06

0.95 ± 0.06

0.95 ± 0.07

0.96 ± 0.05

0.93 ± 0.07

0.82

0.80 ± 0.04

LDL-C (mmol/L)

5.60 ± 0.77

3.94 ± 0.55**

2.92 ± 0.78**†

6.17 ± 0.80

5.02 ± 1.19*

2.87 ± 0.40**†

6.34

4.71 ± 0.42

TG (mmol/L)

1.94 ± 0.62

1.25 ± 0.24*

1.18 ± 0.43*

2.24 ± 0.47

1.43 ± 0.63*

1.29 ± 0.45**

1.25

0.82 ± 0.19

  1. Baseline values were calculated as mean values of the 3 years preceding the start of treatment for patient 1 and patient 2 and as value at the diagnosis, before the start of treatment for patient 3; E10 = ezetimibe 10 mg/day; A10 = atorvastatin 10 mg/day. Wilcoxon test: *P < 0.05 vs baseline; **P < 0.02 vs baseline; †P < 0.02 vs E10. ALT reference 10–45 IU/L; Total Cholesterol (TC) reference value below 5.17 mmol/L, Triglycerides (TG) reference value 0.3–1.7 mmol/L, HDL cholesterol (HDL-C) reference value above 1.16 mmmol/L, LDL cholesterol (LDL-C) reference value below 3.36 mmol/L